Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Oral Kanglaite (KLTc)in Men With Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc on Prostate Specific Antigen (PSA) Doubling Time Among Men With Rising PSA Levels After Definitive Local Therapy

NCT01483586 is registered in ClinicalTrials.gov with KangLaiTe USA as lead sponsor.

NCT NCT01483586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01483586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Oral Kanglaite (KLTc)in Men With Prostate Cancer: Randomized, Dose-Ranging Study of the Effects of KLTc on Prostate Specific Antigen (PSA) Doubling Time Among Men With Rising PSA Levels After Definitive Local Therapy
Lead sponsor
KangLaiTe USA
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2011
Completion date
December 31, 2013
Enrollment
90 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer